Aclaris Therapeutics - ACRS Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRS shares.
View ACRS analyst ratings or view top-rated stocks.

7 analysts have issued 1-year price objectives for Aclaris Therapeutics' shares. Their ACRS share price forecasts range from $21.00 to $43.00. On average, they predict the company's share price to reach $32.00 in the next year. This suggests a possible upside of 295.6% from the stock's current price.
View analysts price targets for ACRS or view top-rated stocks among Wall Street analysts.

Aclaris Therapeutics' stock was trading at $15.75 at the beginning of the year. Since then, ACRS stock has decreased by 48.6% and is now trading at $8.09.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our ACRS earnings forecast.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its quarterly earnings results on Thursday, February, 23rd. The biotechnology company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.03. The biotechnology company earned $7.80 million during the quarter, compared to analysts' expectations of $1.99 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 41.71% and a negative net margin of 292.11%. The company's revenue was up 420.0% on a year-over-year basis. During the same period last year, the firm earned ($0.37) EPS.

ETFs with the largest weight of Aclaris Therapeutics (NASDAQ:ACRS) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX).

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACRS stock can currently be purchased for approximately $8.09.

Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $539.52 million and generates $29.75 million in revenue each year. The biotechnology company earns $-86,910,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344.